Drug Monograph

Drug/Drug Class:	**BUTRANS™ (buprenorphine) transdermal patch/ Long-acting opioid**
Prepared for:	MO HealthNet
Prepared by:	Xerox Heritage, LLC

☒ **New Criteria** ☐ **Revision of Existing Criteria**

Executive Summary

Purpose:	The purpose of this monograph is to provide a review of new therapy to determine whether the reviewed drug should be made available on an open access basis to prescribers, require a clinical edit or require prior authorization for use.
Dosage Forms:	Each Butrans™ 7.5 mcg/hr patch contains 7.5 mg of total buprenorphine content with an active surface area of 9.375 cm^2 to be applied weekly.
Manufacturer:	Manufactured by: LTS Lohmann Therapy Systems Corp., West Caldwell, NJ 07006 USA Manufactured for: Purdue Pharma L.P., Stamford, CT 06901 USA
Indications:	Butrans™ is a long-acting opioid agonist indicated for the treatment of severe chronic pain that requires around-the-clock treatment for which short-acting opioids are inadequate.
Costs:	$238.72 per month of Butrans™ Wholesale Acquisition Cost
Summary of Findings:	This drug is being considered for inclusion in the state specific Preferred Drug List.
Status Recommendation:	☐ Prior Authorization (PA) Required ☐ Open Access ☐ Fiscal Edit ☒ PDL
Type of PA Criteria:	☐ Increased Risk of ADE ☐ Non-Preferred Agent ☐ Appropriate Indications ☒ Preferred Agent

Prepared By: Abbey Mahaney, Pharm. D. Candidate 2015
Date: October 22, 2014

© 2014 Xerox Heritage, LLC All Rights Reserved.